This is happening RIGHT NOW. There is not much retrospective about excess deaths screaming higher TODAY.
So many nails it's in an iron coffin by now. Meeting Coverage > CROI Higher Dose of Ivermectin, and for Longer, Still No Help Against COVID — Losing streak continues for controversial antiparasitic by Ed Susman, Contributing Writer, MedPage TodayFebruary 23, 2023 "These findings do not support the use of ivermectin in outpatients with COVID-19," said Naggie. One death and four hospitalizations occurred in the ivermectin group versus no deaths and two hospitalizations in the placebo group. Overall, adverse events (AEs) were uncommon in both arms. Results of the trial were published simultaneously in JAMAopens in a new tab or window. In an accompanying editor's noteopens in a new tab or window, JAMA Editor-in-Chief Kirsten Bibbins-Domingo, MD, PhD, and Preeti Malani, MD, MSJ, the journal's deputy editor, pointed out that a 2022 Cochrane meta-analysisopens in a new tab or window of 11 eligible studies showed no benefit with ivermectin for COVID-19, and that three randomized trials since then have all reached the same conclusion. Yet the negative trials failed to silence proponents of the controversial antiparasitic, with criticism often lobbed at the dosage selected or duration of treatment used in trials. "Today JAMA publishes a new trial of ivermectin treatment for mild to moderate COVID-19 that addresses the possibility that the existing literature may have missed the efficacy of ivermectin because the previously tested dose -- approximately 400 μg/kg daily for 3 daysopens in a new tab or window -- was insufficient," they wrote. "At a higher treatment dose -- 600 μg/kg daily and longer treatment duration of 6 days, Naggie and colleagues again conclude that ivermectin is not beneficial for the treatment of COVID-19." Although AEs were not significantly different between the ivermectin and placebo groups, Bibbins-Domingo and Malani cautioned that ivermectin treatment for COVID-19 could still be harmful, particularly if it delays the use of other proven interventions. Naggie's group said a strength of the current study was that 83.5% had received at least two doses of vaccine, "thus representing a highly relevant study population," noting that past ivermectin trials had excluded vaccinated participants. No different effect by vaccination status was seen for the primary endpoint of time to sustained recovery, which was defined as at least 3 consecutive days without symptoms. In an accompanying editorialopens in a new tab or window, Alex John London, PhD, of Carnegie Mellon University in Pittsburgh, and Christopher Seymour, MD, of the University of Pittsburgh, highlighted that despite all the evidence against it thus far, ivermectin studies continued, perhaps at the expense of other more fruitful endeavors. "Decisions about what investigations to undertake must be responsive to the relative social value of continuing to reduce uncertainty around one intervention, and stakeholders must consider whether scarce time, resources, and participant effort could be better invested examining other questions," they wrote. The current arm of the ACTIV-6 platform trial recruited from February 2022 to July 2022 at 93 sites in the U.S., and ultimately included 1,206 participants with confirmed COVID-19. Participants were randomized to ivermectin at a daily targeted maximum dose of 600 μg/kg for 6 days (n=602) or placebo (n=604). Participants had a median age of 48 years, about 60% were women, and three-fourths were white. About a quarter of the individuals had hypertension, 13-16% had asthma, and 9% had diabetes. Participants had to have at least two COVID-19 symptoms for no longer than 7 days before enrollment. From symptom onset, the median time to enrollment was 3 and 60% received treatment within 5 days. Exclusion criteria included hospitalization, ivermectin use within the past 14 days, and known allergy or contraindication to the study drug. Concurrent use of standard therapies for COVID-19 was allowed. Here, 2.5% of patients on the ivermectin arm received nirmatrelvir-ritonavir (Paxlovid) versus 4.3% of placebo patients. Other treatments included the use of monoclonal antibodies in 4.2% and 3.6%, respectively, and molnupiravir in 0.2% and 0.8%. Ed Susman is a freelance medical writer based in Fort Pierce, Florida, USA. Disclosures ACTIV-6 was funded by the National Center for Advancing Translational Sciences (NCATS) and supported by the Office of the Assistant Secretary for Preparedness and Response and the Biomedical Advanced Research and Development Authority. Naggie disclosed relationships with Gilead, AbbVie, Pardes Biosciences, Silverback Therapeutics, Vir Biotechnology, Personal Health Insights, and Bristol Myers Squibb/PRA Health Sciences. Bibbins-Domingo, Malani, and London disclosed no relationships with industry. Seymour disclosed relationships with Inotrem and Beckman Coulter, as well as support from the National Institute of General Medical Sciences. Primary Source JAMA Source Reference: opens in a new tab or windowNaggie S, et al "Effect of higher-dose ivermectin for 6 days vs placebo on time to sustained recovery in outpatients with COVID-19: a randomized clinical trial" JAMA 2023; DOI: 10.1001/jama.2023.1650. Secondary Source JAMA Source Reference: opens in a new tab or windowLondon AJ, Seymour CW "The ethics of clinical research: managing persistent uncertainty" JAMA 2023; DOI: 10.1001/jama.2023.1675. Additional Source JAMA Source Reference: opens in a new tab or windowBibbins-Domingo K, Malani PN "At a higher dose and longer duration, ivermectin still not effective against COVID-19" JAMA 2023; DOI: 10.1001/jama.2023.1922.
Darwin seemly catches up with many Covidiots. Escaping the COVID vaccine drove a Michigan man to the South Pacific. Two years later, his family isn’t sure what happened next. https://www.audacy.com/wwjnewsradio...o-michigan-man-trying-to-escape-covid-vaccine The COVID-19 pandemic hit nearly three years ago, shedding light on a massive nationwide issue: mental health. For some the coronavirus and everything that changed with the pandemic was too much. In 2020, 20-year-old Isaac Danian of Grand Rapids, Mich., fled the country after falling deeply into COVID conspiracy theories, in an attempt to avoid the vaccine and testing. After finding his way to the South Pacific, the French government told his mother he had drowned. On a new Daily J, WWJ’s Zach Clark learns it’s not really clear what exactly happened to Isaac, as he hears from his mother, Abigail, and gets insight from mental health experts on the toll the pandemic has taken on some. (Article has video)
AGAIN, why are all these people who got five vaccines still up and running, why aren't they dead and disabled like you predicted?
LOL says the guy who thought mentioning a doctor being a Trump supporter from Florida was relevant. Why isn’t he pushing the jabs then like your vaccine messiah?
Because the excess deaths aren’t from COVID you retard. Just follow the 9 sigma event occurring right now with respect to non COVID natural cause death. LOL. You are fucking brain dead. Like talking to a petulant child (who for some reason has taken 5 vaccines!!!)